Evidence map›Paper›PMID 29389848›Full record

ArticlePharmaceutics2018

Feasibility of Using Gluconolactone, Trehalose and Hydroxy-Propyl Gamma Cyclodextrin to Enhance Bendroflumethiazide Dissolution Using Lyophilisation and Physical Mixing Techniques.

Ashraf Saleh, Kenneth McGarry, Cheng Shu Chaw, Amal Ali Elkordy

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ashraf SalehSchool of Pharmacy and Pharmaceutical Sciences, University of Sunderland, Sunderland SR1 3SD, UK. bg44ce@research.sunderland.ac.uk.
Kenneth McGarrySchool of Pharmacy and Pharmaceutical Sciences, University of Sunderland, Sunderland SR1 3SD, UK. ken.mcgarry@sunderland.ac.uk.
Cheng Shu ChawSchool of Pharmacy and Pharmaceutical Sciences, University of Sunderland, Sunderland SR1 3SD, UK. cheng.chaw@sunderland.ac.uk.
Amal Ali ElkordySchool of Pharmacy and Pharmaceutical Sciences, University of Sunderland, Sunderland SR1 3SD, UK. amal.elkordy@sunderland.ac.uk.ORCID 0000-0002-0781-1127
University of Sunderland · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeHydrophobic drugs are facing a major challenge in dissolution rate enhancement and solubility in aqueous solutions; therefore, a variety of methods have been used to improve dissolution rate and/or solubility of bendroflumethiazide as a model hydrophobic drug.

methodsIn this study, two main methods (physical mixing and lyophilisation) were used with gluconolactone, hydroxyl propyl γ-ccyclodextrin, and trehalose to explore this challenge. Bendroflumethiazide, practically insoluble in water, was mixed with one of the three excipients gluconolactone, hydroxyl propyl γ-cyclodextrin, and trehalose in three different ratios 1:1, 1:2, 1:5. To the best of our knowledge, the dissolution of the drug has not been previously enhanced by using either these methods or any of the used excipients. Samples containing drug and each of the excipients were characterized via dissolution testing, Fourier Transform infra-red spectroscopy, differential scanning calorimetry, and scanning electron microscopy.

resultsThe used methods showed a significant enhancement in dug dissolution rate; physical mixing significantly,

conclusionsthe physical mixing and freeze drying processes significantly increased the percentage of drug release with time.

Indexed as

bendroflumethiazidedissolution rategluconolactonehydrophobic drughydroxyl propyl γ-cyclodextrinlyophilisationtrehalose

Identifiers

PMID29389848
PMCPMC5874835
OpenAlexW2788823403

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.